WallStreetZenWallStreetZen

NYSEMKT: OSTX
Os Therapies Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for OSTX

Based on 2 analysts offering 12 month price targets for Os Therapies Inc

Min Forecast
$19.00+998.27%
Avg Forecast
$19.50+1,027.17%
Max Forecast
$20.00+1,056.07%

Should I buy or sell OSTX stock?

Based on 2 analysts offering ratings for Os Therapies Inc.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although OSTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates OSTX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their OSTX stock forecasts and price targets.

OSTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-07
lockedlocked$00.00+00.00%2025-04-02

1 of 1

Forecast return on equity

Is OSTX forecast to generate an efficient return?

Company
-134.23%
Industry
121.38%
Market
-46.31%
OSTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is OSTX forecast to generate an efficient return on assets?

Company
132.23%
Industry
46.94%
OSTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

OSTX earnings per share forecast

What is OSTX's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.54
Avg 2 year Forecast
-$0.37
Avg 3 year Forecast
$0.01

OSTX revenue forecast

What is OSTX's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$20.2M
Avg 2 year Forecast
$40.8M
Avg 3 year Forecast
$61.8M

OSTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
OSTX$1.73$19.50+1,027.17%Strong Buy
DTIL$4.38$60.00+1,269.86%Buy
PRLD$0.86$4.50+424.48%Buy
INKT$12.06$35.00+190.22%Hold
ATNM$1.54$4.00+159.74%Buy
View Top Biotech Stocks

Os Therapies Stock Forecast FAQ

Is Os Therapies Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSEMKT: OSTX) stock is to Strong Buy OSTX stock.

Out of 2 analysts, 2 (100%) are recommending OSTX as a Strong Buy, 0 (0%) are recommending OSTX as a Buy, 0 (0%) are recommending OSTX as a Hold, 0 (0%) are recommending OSTX as a Sell, and 0 (0%) are recommending OSTX as a Strong Sell.

If you're new to stock investing, here's how to buy Os Therapies stock.

What is OSTX's earnings growth forecast for 2025-2027?

(NYSEMKT: OSTX) Os Therapies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.23%.

Os Therapies's earnings in 2025 is -$13,272,780.On average, 1 Wall Street analyst forecast OSTX's earnings for 2025 to be -$15,172,756, with the lowest OSTX earnings forecast at -$15,172,756, and the highest OSTX earnings forecast at -$15,172,756. On average, 1 Wall Street analyst forecast OSTX's earnings for 2026 to be -$10,396,148, with the lowest OSTX earnings forecast at -$10,396,148, and the highest OSTX earnings forecast at -$10,396,148.

In 2027, OSTX is forecast to generate $280,977 in earnings, with the lowest earnings forecast at $280,977 and the highest earnings forecast at $280,977.

What is OSTX's revenue growth forecast for 2026-2028?

(NYSEMKT: OSTX) Os Therapies's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.98%.

Os Therapies's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast OSTX's revenue for 2026 to be $567,573,479, with the lowest OSTX revenue forecast at $567,573,479, and the highest OSTX revenue forecast at $567,573,479. On average, 1 Wall Street analysts forecast OSTX's revenue for 2027 to be $1,146,386,038, with the lowest OSTX revenue forecast at $1,146,386,038, and the highest OSTX revenue forecast at $1,146,386,038.

In 2028, OSTX is forecast to generate $1,736,999,629 in revenue, with the lowest revenue forecast at $1,736,999,629 and the highest revenue forecast at $1,736,999,629.

What is OSTX's forecast return on assets (ROA) for 2025-2028?

(NYSEMKT: OSTX) forecast ROA is 132.23%, which is higher than the forecast US Biotechnology industry average of 46.94%.

What is OSTX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year OSTX price target, the average OSTX price target is $19.50, with the highest OSTX stock price forecast at $20.00 and the lowest OSTX stock price forecast at $19.00.

On average, Wall Street analysts predict that Os Therapies's share price could reach $19.50 by Aug 7, 2026. The average Os Therapies stock price prediction forecasts a potential upside of 1,027.17% from the current OSTX share price of $1.73.

What is OSTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSEMKT: OSTX) Os Therapies's current Earnings Per Share (EPS) is -$0.86. On average, analysts forecast that OSTX's EPS will be -$0.54 for 2025, with the lowest EPS forecast at -$0.54, and the highest EPS forecast at -$0.54. On average, analysts forecast that OSTX's EPS will be -$0.37 for 2026, with the lowest EPS forecast at -$0.37, and the highest EPS forecast at -$0.37. In 2027, OSTX's EPS is forecast to hit $0.01 (min: $0.01, max: $0.01).

What is OSTX's forecast return on equity (ROE) for 2025-2028?

(NYSEMKT: OSTX) forecast ROE is -134.23%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.